A single-walled carbon nanotube (a sheet of hexagons in a tubular shape) on a blurred background of other carbon nanotubes

Scientists engineered single-walled carbon nanotubes to detect biomarkers in blood.

Credit: iStock/enot-poloskun

A molecular nose sniffs out ovarian cancer

Researchers developed a carbon nanotube-based sensor paired with a machine learning algorithm to diagnose ovarian cancer with better specificity and sensitivity than current methods.
Nathan Holwell
| 3 min read
Register for free to listen to this article
Listen with Speechify
0:00
3:00

If clinicians detect ovarian cancer before it metastasizes, the survival rate is greater than 90%. The problem is that clinicians diagnose ovarian cancer using serum biomarker detection combined with transvaginal ultrasonography, but these methods cannot detect the cancer early enough to reduce mortality.

To design a more sensitive ovarian cancer diagnostic tool, Daniel Heller, a biomedical engineer at Memorial Sloan Kettering Cancer Center and author of a new study, and his team developed a nanosensor based on single-walled carbon nanotubes (1). When they paired this nanotube sensor with a machine learning model, they detected ovarian cancer with greater sensitivity than current methods and identified new biomarkers for the disease, potentially allowing for earlier cancer detection and better health outcomes.

“Hysterectomy, where they remove the ovaries, fallopian tubes, and the uterus, is a good preventive surgery, but it also causes premature menopause. If you can actually just detect early, that would be the best. Then those kinds of procedures wouldn't have to be done nearly as often,” said Heller.

Heller’s carbon nanotube-based sensor, or “molecular nose,” uses a perception-based strategy to detect more molecules than the number of sensors it has, akin to how humans differentiate many more smells than we have smell receptors. The sensing of a combination of different molecules by smell receptors leads to a unique smell sensation.

Carbon nanotubes look like tiny stretches of chicken wire rolled into a tube. To detect different ovarian cancer biomarkers, Heller’s team modified their nanotubes with small chemical groups called organic color centers (OCC) and then wrapped them with single-stranded DNA molecules. The DNA wrapping facilitates suspending the nanotubes in a liquid solution such as blood serum and enhances the nanotubes’ molecular selectivity. When molecules in the local environment interact with OCCs, the distinct infrared wavelengths emitted by the OCCS can be measured with a spectroscopic apparatus. 

Heller’s team collected information from their carbon nanotube sensors and trained a machine learning model to distinguish between healthy and ovarian cancer samples.

While the combination of a sensitive and specific nanosensor without the machine learning model enabled differentiation between high-grade ovarian cancer samples and healthy ones, the system could not differentiate high-grade ovarian cancer from other disease conditions, but it could do so when machine learning was applied, differentiating conditions such as endometriosis, low-grade ovarian cancer, and non-gynecologic cancers. The sensor technology performed better than the current clinical screen, a combination of longitudinal cancer biomarker 125 (CA-125) and second-line transvaginal ultrasonography.

“I suspect that if they had a combination of this nanosensor with CA-125 and transvaginal ultrasonography, they might discover that their detection rate here is close to 100%, which is better than the current CA-125 biomarker assay and transvaginal ultrasonography,” said Ray Iles, the chief scientific officer at the clinical diagnostics company MAP Sciences who was not involved in the study. “Don't look at it in isolation. Look at [it] in combination.”

Although Heller and his team envisioned their new sensor solely as a detection method, it may also have biomarker discovery applications. When the researchers individually eliminated each spectroscopic variable from the machine learning analysis to understand how it affected the model’s performance while accounting for any interference from drugs or other chronic conditions, they discovered that some serum markers that were not previously considered ovarian cancer biomarkers were more important to the model performance than the known biomarkers.

Heller and his team hope to develop this technology for detecting early-stage ovarian cancer and to determine if this technology can be used to detect other cancer types, especially those that can be cured when detected early.

“This kind of technology moves in a direction parallel to self-driving cars and other technologies that use AI and machine learning. One could continue to train this technology to detect more and more things and to get better and better,” said Heller.

Reference

  1. Kim, M. et al. Detection of ovarian cancer via the spectral fingerprinting of quantum-defect-modified carbon nanotubes in serum by machine learning. Nat Biomed Eng  6, 267-275 (2022).

About the Author

  • Nathan Holwell
    Nathan is a biomedical engineering PhD candidate at Queen’s University and a science journalism intern at DDN.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue